VALIANTORG NSE filing

Valiant Organics Q2 FY27 Revenue Rises 93.4% YoY to ₹3,042 Mn

The RealCase readHigh impact Positive

Valiant Organics reported Q2 FY27 revenue of ₹3,042 Mn, up 93.4% YoY. H1 FY27 revenue reached ₹5,358 Mn, up 48.1% YoY. Q2 FY27 PAT was ₹173 Mn, a significant increase from ₹57 Mn in Q2 FY26. H1 FY27 PAT was ₹466 Mn, up from ₹139 Mn in H1 FY26. Sales volumes grew 43% YoY in Q2 FY27.

Why it matters

The announcement contains detailed financial results with significant year-on-year growth in revenue and profit, which are material information for investors and will likely impact the company's stock price.

The market read

The company has reported strong year-on-year growth in revenue and profit for both the quarter and half-year ended September 30, 2026, indicating positive business performance.

Valiant Organics Limited has announced its financial results for the quarter and half-year ended September 30, 2026. The company reported an operational revenue of ₹3,042 Mn for Q2 FY27, marking a significant year-on-year increase of 93.4% from ₹1,573 Mn in Q2 FY26. For the half-year ended September 30, 2026 (H1 FY27), operational revenue stood at ₹5,358 Mn, up 48.1% from ₹3,617 Mn in H1 FY26.

The company's EBITDA for Q2 FY27 was ₹390 Mn, an 84.0% increase from ₹212 Mn in the prior year's quarter, though the EBITDA margin saw a slight decrease to 12.82% from 13.48% due to rising raw material costs. For H1 FY27, EBITDA grew by 75.6% to ₹806 Mn, with an improved EBITDA margin of 15.04% compared to 12.69% in H1 FY26.

Profit After Tax (PAT) for Q2 FY27 was ₹173 Mn, a substantial rise from ₹57 Mn in Q2 FY26. The PAT margin for the quarter was 5.69%. For H1 FY27, PAT surged to ₹466 Mn from ₹139 Mn in H1 FY26, with a PAT margin of 8.70%.

Sales volumes in Q2 FY27 increased by 28% quarter-on-quarter and 43% year-on-year. Hydrogenation volumes grew by 27% QoQ, contributing 56% of the quarterly revenue, primarily driven by higher Para Amino Phenol output. Ammonolysis volumes increased by 60% QoQ. Chlorination volumes grew 4% QoQ, but revenue saw a slight dip due to lower chlorophenol realisations. Capital expenditure for H1 FY27 was ₹263 Mn, allocated towards the Sarigam and Jhagadia units.

The company also noted that its material step-down subsidiary, Valiant Laboratories Limited (VLL), has become an associate company due to dilution of stake following an IPO. Consequently, consolidated financial results for previous periods are not comparable.

Filing to action

What to do with a filing like this

Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.

View original filing